Subtype
Kidney and Ureter Neoplasm
CI-CAN-00001051Explore in graph →
Non-malignant518 active trials17 approved drugs81 evidence items
- NCIt
- C7514
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001051Explore in graph →
Clinical trials
2,410 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05808608 | A Study of AK104 Plus Axitinib in Advanced/Metastatic Special Pathological Subtypes of Renal Cell Carcinoma | active not recruiting | Phase 1 / Phase 2 | 37 | Hao ZengOTHER | 1 | Apr 7, 2026 | clinicaltrials |
| NCT06444815 | A Study of VET3-TGI in Patients With Solid Tumors(STEALTH-001) | recruiting | Phase 1 | 60 | KaliVir ImmunotherapeuticsINDUSTRY | 1 | Apr 7, 2026 | clinicaltrials |
| NCT05703269 | Comparing Single vs Multiple Dose Radiation for Cancer Patients With Brain Metastasis and Receiving Immunotherapy(HYPOGRYPHE) | active not recruiting | N/A | 58 | Wake Forest University Health SciencesOTHER | 1 | Apr 6, 2026 | clinicaltrials |
| NCT03526250 | Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial) | completed | Phase 2 | 23 | National Cancer Institute (NCI)NIH | 2 | Apr 3, 2026 | clinicaltrials |
| NCT03841149 | Volume 3D_US Kidney(VolUS3D) | completed | — | 53 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Apr 3, 2026 | clinicaltrials |
| NCT06376669 | Stereotactic Body Proton Therapy for Treatment of Primary Renal Cell Carcinoma(SPARE) | recruiting | Phase 2 | 20 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Apr 3, 2026 | clinicaltrials |
| NCT02664883 | Myeloid Derived Suppressor Cells Clinical Assay in Finding Kidney Cancer | active not recruiting | — | 37 | University of Southern CaliforniaOTHER | 1 | Apr 2, 2026 | clinicaltrials |
| NCT03798626 | Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers | completed | Phase 1 | 167 | Novartis PharmaceuticalsINDUSTRY | 15 | Apr 1, 2026 | clinicaltrials |
| NCT06222593 | Study to Evaluate the Safety and Efficacy of Bicalutamide in Combination With Sunitinib in Patients With TKIs-resistant RCC | recruiting | Phase 1 / Phase 2 | 28 | State University of New York at BuffaloOTHER | 1 | Apr 1, 2026 | clinicaltrials |
| NCT06532422 | Study of Post-operative Complications After Laparoscopic Outpatient Nephrectomy(NEPHRAMBU) | recruiting | — | 50 | GCS Ramsay Santé pour l'Enseignement et la RechercheOTHER | 1 | Apr 1, 2026 | clinicaltrials |
| NCT07197580 | Phase 3 Study to Assess Safety and Efficacy of 177Lu-TLX250 in Advanced Relapsed or Recurrent ccRCC(LUTEON) | recruiting | Phase 3 | 40 | Telix Pharmaceuticals (Innovations) Pty LimitedINDUSTRY | 1 | Apr 1, 2026 | clinicaltrials |
| NCT07234656 | Patient-partnered Research in Investigating Fear of Cancer Recurrence in Kidney Cancer(PP-RECURK) | recruiting | — | 105 | Brigitta Rasmussen VillumsenOTHER | 1 | Apr 1, 2026 | clinicaltrials |
| NCT02555748 | Therapeutic Drug Monitoring of Sunitinib and Pazopanib in Advanced or Metastatic Renal Cell Carcinoma(SUP-R) | completed | Phase 4 | 47 | Institut Claudius RegaudOTHER | 1 | Mar 31, 2026 | clinicaltrials |
| NCT07502716 | Compassionate Use of Ubamatamab | available | — | — | Regeneron PharmaceuticalsINDUSTRY | 0 | Mar 31, 2026 | clinicaltrials |
| NCT03786796 | Study of Olaparib in Metastatic Renal Cell Carcinoma Patients With DNA Repair Gene Mutations(ORCHID) | recruiting | Phase 2 | 20 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Mar 30, 2026 | clinicaltrials |
| NCT06453642 | Evaluation of a Simple-Prep Controlled Embolic(GPX) | active not recruiting | N/A | 114 | Fluidx Medical Technology, Inc.INDUSTRY | 3 | Mar 30, 2026 | clinicaltrials |
| NCT07500805 | UCL70805F in Patients With CD70-positive Advanced Renal Clear Cell Carcinoma | not yet recruiting | Phase 1 | 21 | UTC Therapeutics Inc.INDUSTRY | 1 | Mar 30, 2026 | clinicaltrials |
| NCT07500831 | Fasting-Mimicking Diet Combined With IO-TKI Combination Therapy in Patients With Metastatic Renal Cell Carcinoma | not yet recruiting | N/A | 43 | Qilu Hospital of Shandong UniversityOTHER | 1 | Mar 30, 2026 | clinicaltrials |
| NCT04234113 | Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors | terminated | Phase 1 | 115 | SOTIO Biotech AGINDUSTRY | 4 | Mar 27, 2026 | clinicaltrials |
| NCT07494435 | Phase 2 Study of WGI-0301 Plus Nivolumab in Patients With HCC and RCC | not yet recruiting | Phase 2 | 230 | Zhejiang Haichang Biotech Co., Ltd.INDUSTRY | 1 | Mar 27, 2026 | clinicaltrials |
| NCT07497958 | Ischemic Preconditioning Reduces the Severity of Acute Kidney Injury After Partial Nephrectomy | not yet recruiting | N/A | 174 | Sun Yat-sen UniversityOTHER | 1 | Mar 27, 2026 | clinicaltrials |
| NCT05024214 | Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors | recruiting | Phase 1 / Phase 2 | 170 | 3D Medicines (Sichuan) Co., Ltd.INDUSTRY | 1 | Mar 25, 2026 | clinicaltrials |
| NCT07492225 | Neoadjuvant Chemotherapy Before Surgery vs Surgery Alone for UTUC: A Randomized Trial | active not recruiting | Phase 2 | 120 | Changhai HospitalOTHER | 1 | Mar 25, 2026 | clinicaltrials |
| NCT07492628 | Dual-Target Nectin-4/HER2 CAR-NK Cells in Advanced Urothelial Carcinoma(DUET-UC-NK) | recruiting | Phase 1 | 42 | Beijing BiotechINDUSTRY | 1 | Mar 25, 2026 | clinicaltrials |
| NCT03288545 | A Study of Enfortumab Vedotin Alone or With Other Therapies for Treatment of Urothelial Cancer(EV-103) | terminated | Phase 1 / Phase 2 | 348 | Astellas Pharma Global Development, Inc.INDUSTRY | 6 | Mar 24, 2026 | clinicaltrials |
| NCT07470840 | SBRT Plus Anlotinib and Bimepolizumab in Locally Advanced or Metastatic Renal Cell Carcinoma | not yet recruiting | Phase 2 | 27 | Fujian Cancer HospitalOTHER_GOV | 1 | Mar 24, 2026 | clinicaltrials |
| NCT06580938 | A Study to Learn About PF-07921585 Alone or With Other Anti-cancer Medicines in People With Cancer | terminated | Phase 1 | 4 | PfizerINDUSTRY | 1 | Mar 23, 2026 | clinicaltrials |
| NCT07488533 | Comparing the Combination of Sullumab and Fruquintinib in Postoperative Adjuvant Therapy for High Recurrence Risk Non Transparent Renal Cell Carcinoma | active not recruiting | Phase 2 | 40 | Sun Yat-sen UniversityOTHER | 1 | Mar 23, 2026 | clinicaltrials |
| NCT07488572 | Safety and Efficacy of Yiwoxidan Anti (AK112) Monotherapy in Patients With Metastatic Renal Clear Cell Carcinoma Who Are Intolerant to TKI Treatment: a Prospective, Single Arm, Phase II Clinical Study | enrolling by invitation | Phase 2 | 60 | Sun Yat-sen UniversityOTHER | 1 | Mar 23, 2026 | clinicaltrials |
| NCT04637594 | Trying to Find the Correct Length of Treatment With Immune Checkpoint Therapy(IMAGINE) | active not recruiting | Phase 3 | 3 | Alliance for Clinical Trials in OncologyOTHER | 1 | Mar 20, 2026 | clinicaltrials |
| NCT04904302 | Sitravatinib and Nivolumab for the Treatment of Metastatic or Advanced Clear Cell Renal Cell Cancer | terminated | Phase 2 | 15 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 20, 2026 | clinicaltrials |
| NCT06126159 | MRI Functional Imaging Characteristics and Fat Quantification of CT-fat-free Renal Neoplasms: Relationships With Histological Classifications and Molecular Markers | active not recruiting | N/A | 44 | Chang Gung Memorial HospitalOTHER | 1 | Mar 20, 2026 | clinicaltrials |
| NCT06882486 | Post-immunotherapy Nephrectomy for Metastatic Kidney Cancer After Complete or Major Response to Systemic Therapy(NAMECAR) | recruiting | N/A | 60 | Institut Paoli-CalmettesOTHER | 1 | Mar 20, 2026 | clinicaltrials |
| NCT07397611 | Pre-NEOSHIFT-RCC: Neoadjuvant HIF-Inhibitor Immunotherapy in RCC | recruiting | Phase 2 | 32 | Dana-Farber Cancer InstituteOTHER | 1 | Mar 20, 2026 | clinicaltrials |
| NCT03185039 | Predictive Impact of MMP2 and MMP9 Levels for Patients With Metastatic Kidney Cancer Treated With Anti-angiogenic Agents | active not recruiting | N/A | 50 | Institut Paoli-CalmettesOTHER | 1 | Mar 19, 2026 | clinicaltrials |
| NCT04338269 | A Study of Atezolizumab in Combination With Cabozantinib Compared to Cabozantinib Alone in Participants With Advanced Renal Cell Carcinoma After Immune Checkpoint Inhibitor Treatment(CONTACT-03) | terminated | Phase 3 | 522 | Hoffmann-La RocheINDUSTRY | 15 | Mar 19, 2026 | clinicaltrials |
| NCT04960059 | NOTION: iN-home Sampling Of cyTokines in ImmunOtherapy patieNts | completed | — | 24 | The Christie NHS Foundation TrustOTHER | 1 | Mar 19, 2026 | clinicaltrials |
| NCT07004426 | Symptomatic and Incidental RCC Detection(KIDCaD) | completed | — | 1,000 | Charles University, Czech RepublicOTHER | 1 | Mar 19, 2026 | clinicaltrials |
| NCT07480044 | A Phase II Clinical Two-Stage Study of Transcranial Magnetic Stimulation in Preventing Postoperative Delirium in Elderly Patients After Urological Surgery | not yet recruiting | N/A | 220 | Zhejiang UniversityOTHER | 1 | Mar 18, 2026 | clinicaltrials |
| NCT05738694 | Neoadjuvant of Axitinib Plus PD-1 to Improve Disease Free Survival of Patients With Renal Cell Carcinoma | recruiting | Phase 3 | 298 | ZHOU FANGJIANOTHER | 1 | Mar 17, 2026 | clinicaltrials |
| NCT06868927 | Targeted Decision Making In Renal Cell Carcinoma Relying on a Radiogenomics Translational Platform(TARGET-RCC) | recruiting | — | 50 | IRCCS San RaffaeleOTHER | 1 | Mar 17, 2026 | clinicaltrials |
| NCT07465458 | Radiofrequency Ablation Multicenter Observational Study in Renal Oncology Patients(RASROP-003) | not yet recruiting | — | 226 | Humanitas Hospital, ItalyOTHER | 2 | Mar 16, 2026 | clinicaltrials |
| NCT02439008 | Early Biomarkers of Tumor Response in High Dose Hypofractionated Radiotherapy Word Package 3 : Immune Response | terminated | N/A | 28 | Centre Oscar LambretOTHER | 1 | Mar 13, 2026 | clinicaltrials |
| NCT03652298 | Effects of a Neuroscience-based Technique on Cancer Patients Announced of a Palliative Disease Progression and Partners(NeuroPrevPTSD) | terminated | Phase 2 | 19 | Centre Oscar LambretOTHER | 1 | Mar 13, 2026 | clinicaltrials |
| NCT03996850 | SPECT/CT for the Characterization of Renal Masses | active not recruiting | — | 102 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Mar 13, 2026 | clinicaltrials |
| NCT07284953 | A Novel Haemostatic Agent for Robotic Partial Nephrectomy(PuraBond) | withdrawn | N/A | 0 | The Royal Wolverhampton Hospitals NHS TrustOTHER_GOV | 1 | Mar 13, 2026 | clinicaltrials |
| NCT06349642 | Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic Platform(ELEPHAS-04) | recruiting | — | 324 | Mayo ClinicOTHER | 1 | Mar 12, 2026 | clinicaltrials |
| NCT07050771 | Comprehensive Multimodal Prehabilitation Alone or With Neoadjuvant Therapy Before Major Cancer Surgery | recruiting | Phase 2 | 148 | The Methodist Hospital Research InstituteOTHER | 1 | Mar 12, 2026 | clinicaltrials |
Data updated 24 days agoSource updated Apr 7, 2026source: clinicaltrials